Evidence map›Paper›PMID 31584146›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2019

Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.

Ali A Alhadab, Joshua Rhein, Lillian Tugume, Abdu Musubire, Darlisha A Williams, Mahsa Abassi, Melanie R Nicol, David B Meya, David R Boulware, Richard C Brundage and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Ali A AlhadabOncology Clinical Pharmacology, Pfizer Inc., 10555 Science Center Dr #2423C, La Jolla, San Diego, CA, 92121, USA. alhad009@umn.edu.ORCID 0000-0002-4008-7011
Joshua RheinInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Lillian TugumeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Abdu MusubireInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Darlisha A WilliamsInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Mahsa AbassiInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Melanie R NicolDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA.
David B MeyaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
David R BoulwareDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Richard C BrundageDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA.
ASTRO-CM Study Team
University of Minnesota · USInfectious Diseases Institute · UGPfizer (United States) · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related MeningitisR01NS086312 · NINDS · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2013 to 2026
$8.3M
Operational Research for Cryptococcal Antigen Screening (ORCAS) of HIV PatientsU01AI125003 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2016 to 2020
$3.4M
Evaluating Antiretroviral Pharmacology in the Female Genital Tract to Optimize HIV PreventionK08AI134262 · NIAID · UNIVERSITY OF MINNESOTA · PI NICOL, MELANIE RAE · 2018 to 2022
$847k
Improving Outcomes of HIV-Associated Cryptococcosis in Resource-Limited SettingsK01TW010268 · FIC · UNIVERSITY OF MINNESOTA · PI RHEIN, JOSHUA R · 2016 to 2020
$703k
Epidemiology, Immunopathogenesis, and Outcomes of Non-traumatic Spinal Cord Injury in UgandaK43TW010718 · FIC · INFECTIOUS DISEASES INSTITUTE · PI MUSUBIRE, ABDU KISEKKA · 2017 to 2021
$514k
FIC NIH HHS K01 TW010268FIC NIH HHS K43 TW010718National Center for Advancing Translational Sciences of the National Institute of Health Award UL1TR000114NCATS NIH HHS UL1 TR000114NIAID NIH HHS K08 AI134262NIAID NIH HHS U01 AI125003NINDS NIH HHS R01 NS086312NINDS NIH HHS R01NS086312
6 · The paper itself

Abstract

The ASTRO-CM dose-finding pilot study investigated the role of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis in HIV-infected Ugandan patients. The present study is a post hoc pharmacokinetic-pharmacodynamic analysis of the ASTRO-CM pilot study to provide insight into sertraline exposure-response-outcome relationships. We performed a population pharmacokinetic analysis using sertraline plasma concentration data and correlated various predicted PK-PD indices with the percentage change in log

Indexed as

AdultAmphotericin BAntifungal AgentsBrainCerebrospinal FluidFemaleFluconazoleHIV InfectionsHumansMaleMeningitis, CryptococcalPilot ProjectsSertralineUgandaAmphotericin BAntifungal AgentsFluconazoleSertralineFungal clearanceHIV-associated cryptococcal meningitisPharmacodynamicsPharmacokineticsSertralineSurvival

Identifiers

PMID31584146
PMCPMC7004416
OpenAlexW2979140567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.